CO5570664A2 - Derivados de acidos 2-hidroxi-3(2-indan-2-il-1,1-dimetil-etilamino)-propoxi-fenil-propionico y composiciones farmaceuticas que los contienen como agentes calciliticos - Google Patents

Derivados de acidos 2-hidroxi-3(2-indan-2-il-1,1-dimetil-etilamino)-propoxi-fenil-propionico y composiciones farmaceuticas que los contienen como agentes calciliticos

Info

Publication number
CO5570664A2
CO5570664A2 CO05050416A CO05050416A CO5570664A2 CO 5570664 A2 CO5570664 A2 CO 5570664A2 CO 05050416 A CO05050416 A CO 05050416A CO 05050416 A CO05050416 A CO 05050416A CO 5570664 A2 CO5570664 A2 CO 5570664A2
Authority
CO
Colombia
Prior art keywords
indan
dimethyl
phenyl
propoxy
hydroxy
Prior art date
Application number
CO05050416A
Other languages
English (en)
Inventor
Robert W Marquis
James Francis Callahan
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5570664A2 publication Critical patent/CO5570664A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- en la cual R1 y R5 son independientemente seleccionados del grupo que consiste en H y halógeno;R2, R3 y R4 son independientemente seleccionados del grupo que consiste en H, halógeno y J-K en donde:J es un enlace covalente, alquileno o alquenilo; y K es seleccionado del grupo de CO2R8, siendo R8 H o alquilo;R6 es seleccionado del grupo que consiste en H o alquilo;R7 es seleccionado del grupo que consiste en arilo o arilo condensado, dihidro, tetrahidro arilo condensado, heteroarilo, sin substituir o substituidos con cualquier substituyente seleccionado del grupo que consiste en OH, halógeno, alquilo C1-4, alcoxilo C1-4, cicloalquilo C3-6, CF3, OCF3, CN y NO2;y sales y complejos farmacéuticamente aceptables de los mismos.2.- Un compuesto de acuerdo con la reivindicación 1, seleccionado del grupo que consiste en clorhidrato de ácido (E)-3-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-acrílico;clorhidrato de ácido 3-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)propoxi]-fenil}-propiónico;clorhidrato de éster etílico del ácido 3-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-propiónico;clorhidrato de ácido (E)-3-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-pent-4-enoico;clorhidrato de ácido 5-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)propoxi]-fenil}-pentanoico;éster etílico del ácido 5-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetiI-etil-amino)-propoxi]-fenil}-pentanoico; clorhidrato de éster etílico del ácido 3-{4-bromo-3-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-propiónico;clorhidrato de ácido 3-{4-bromo-3-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)propoxi]-fenil}-propiónico;clorhidrato de ácido 3-{2,3-difluor-4-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)propoxi]-fenil}-propiónico;clorhidrato de éster etílico del ácido 3-{2,3-difluor-4-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-propiónico; ...
CO05050416A 2002-11-26 2005-05-24 Derivados de acidos 2-hidroxi-3(2-indan-2-il-1,1-dimetil-etilamino)-propoxi-fenil-propionico y composiciones farmaceuticas que los contienen como agentes calciliticos CO5570664A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42910502P 2002-11-26 2002-11-26

Publications (1)

Publication Number Publication Date
CO5570664A2 true CO5570664A2 (es) 2005-10-31

Family

ID=32393505

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05050416A CO5570664A2 (es) 2002-11-26 2005-05-24 Derivados de acidos 2-hidroxi-3(2-indan-2-il-1,1-dimetil-etilamino)-propoxi-fenil-propionico y composiciones farmaceuticas que los contienen como agentes calciliticos

Country Status (33)

Country Link
US (6) US7514473B2 (es)
EP (1) EP1569892B1 (es)
JP (1) JP4489597B2 (es)
KR (2) KR101142697B1 (es)
CN (1) CN1325466C (es)
AP (1) AP2113A (es)
AR (1) AR042132A1 (es)
AU (1) AU2003291157C1 (es)
BR (1) BR0316544A (es)
CA (1) CA2507226C (es)
CO (1) CO5570664A2 (es)
CY (1) CY1113083T1 (es)
DK (1) DK1569892T3 (es)
EA (1) EA009603B1 (es)
ES (1) ES2388277T3 (es)
HK (1) HK1082914A1 (es)
IL (1) IL168704A (es)
IS (1) IS2897B (es)
MA (1) MA27528A1 (es)
MX (1) MXPA05005574A (es)
MY (1) MY143244A (es)
NO (1) NO332304B1 (es)
NZ (1) NZ540275A (es)
OA (1) OA12962A (es)
PE (1) PE20040845A1 (es)
PL (1) PL211571B1 (es)
PT (1) PT1569892E (es)
SI (1) SI1569892T1 (es)
TW (1) TWI316511B (es)
UA (1) UA81642C2 (es)
UY (1) UY28089A1 (es)
WO (1) WO2004047751A2 (es)
ZA (1) ZA200504104B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28089A1 (es) 2002-11-26 2004-06-30 Smithkline Beecham Corp Compuestos calciliticos
US20070155819A1 (en) * 2004-02-06 2007-07-05 Marquis Robert W Jr Calcilytic compounds
TW200845956A (en) * 2006-12-18 2008-12-01 Smithkline Beecham Corp Calcilytic compounds
CA2726610C (en) * 2008-06-05 2015-05-05 Asahi Kasei Pharma Corporation Sulfonamide compounds and use thereof
ES2412408T3 (es) * 2008-12-24 2013-07-11 Daiichi Sankyo Company, Limited Compuestos de indanilo
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
WO2015196205A1 (en) * 2014-06-20 2015-12-23 Glaxosmithkline Llc Method of using calcilytic compounds to treat diseases of abnormal glucose or insulin levels

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (es)
US643656A (en) * 1898-09-03 1900-02-20 Francis Keil Mold for lock-cylinders and key-hubs.
ES421076A1 (es) 1973-12-01 1976-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-3-aralquilami-no-2-propanoles.
ES442062A1 (es) 1975-10-24 1977-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-2-hidroxi-3- alquilaminopropanos.
DE2644833A1 (de) 1976-10-05 1978-04-20 Boehringer Sohn Ingelheim Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung
CH618335A5 (es) * 1977-05-31 1980-07-31 Arnegger Richard E
US4234595A (en) 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
IT1101724B (it) * 1978-12-05 1985-10-07 Erba Carlo Spa Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
GB2014968A (en) 1978-02-24 1979-09-05 Pearson J Article handling apparatus
US4495352A (en) 1979-02-13 1985-01-22 Mead Johnson & Company Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
ES480066A1 (es) 1979-04-28 1980-04-01 Especialid Latin Medicam Unive Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos.
DE3544172A1 (de) 1985-12-13 1987-06-19 Lentia Gmbh Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung
FR2601008B1 (fr) 1986-07-03 1990-03-30 Sanofi Sa Procede de synthese stereospecifique de derives de l'indole
DD298506A5 (de) * 1988-12-30 1992-02-27 Ernst-Moritz-Arndt-Universitaet Greifswald,De Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole
DE4040186A1 (de) 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
SG99290A1 (en) * 1996-04-09 2003-10-27 Nps Pharma Inc Calcilytic compounds
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
US20020019440A1 (en) 1996-11-05 2002-02-14 Virbac Sa Aryloxypropanolamine derivatives, method of preparation and applications thereof
US7202261B2 (en) 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
JP2001519813A (ja) 1997-04-04 2001-10-23 スミスクライン・ビーチャム・コーポレイション カルシウム溶解性化合物
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
DE19913753A1 (de) 1998-04-01 1999-10-07 Mannesmann Rexroth Ag Verfahren zur Bildung des Mittelwertes
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
AR018177A1 (es) 1998-04-08 2001-10-31 Smithkline Beecham Corp Compuestos calciliticos, una composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento.
US6335338B1 (en) 1998-08-12 2002-01-01 Smithkline Beecham Corporation Calcilytic compounds
EP1112073A4 (en) 1998-08-12 2002-10-25 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
WO2001007026A2 (en) 1999-07-22 2001-02-01 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
ECSP003590A (es) 1999-07-31 2002-02-25 Smithkline Beecham Corp Compuestos calcioliticos
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
BR0112600A (pt) 2000-07-21 2003-06-24 Smithkline Beecham Corp Compostos calcilìticos
CZ20031144A3 (cs) 2000-10-25 2004-08-18 Smithklineábeechamácorporation Kalcilytické sloučeniny
ES2273909T3 (es) 2000-10-25 2007-05-16 Smithkline Beecham Corporation Compuestos calciliticos.
AU2002254136A1 (en) 2001-03-08 2002-09-24 Smithkline Beecham Corporation Pcra helicase inhibitors
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
UY28089A1 (es) 2002-11-26 2004-06-30 Smithkline Beecham Corp Compuestos calciliticos
ATE489368T1 (de) 2003-04-07 2010-12-15 Nps Pharma Inc Pyrimidinonverbindungen als calcilytica
US20070010571A1 (en) 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
TW200524892A (en) 2003-09-24 2005-08-01 Glaxo Group Ltd Calcilytic compounds
WO2005030746A1 (en) 2003-09-24 2005-04-07 Glaxo Group Limited Calcilytic compounds
EP1713767A4 (en) 2004-02-06 2008-01-16 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
NL1025457C1 (nl) 2004-02-11 2005-08-12 Rudolf Johannes Gerardus Hoorn Haspelrem.
CA2576279A1 (en) 2004-11-08 2006-05-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
EP1846380A4 (en) 2005-01-21 2010-02-17 Nicox Sa HETEROCYCLIC NITROGEN MONOXIDE DONOR COMPOSITIONS CONTAINING CARDIOVASCULAR COMPOUNDS, AND METHODS OF USING THE SAME

Also Published As

Publication number Publication date
PL211571B1 (pl) 2012-05-31
US20150183723A1 (en) 2015-07-02
CA2507226A1 (en) 2004-06-10
TWI316511B (en) 2009-11-01
US20060058391A1 (en) 2006-03-16
US7514473B2 (en) 2009-04-07
EA009603B1 (ru) 2008-02-28
AU2003291157C1 (en) 2011-05-12
PE20040845A1 (es) 2004-11-28
KR20110124806A (ko) 2011-11-17
US20140057980A1 (en) 2014-02-27
CN1741985A (zh) 2006-03-01
JP4489597B2 (ja) 2010-06-23
OA12962A (en) 2006-10-13
US8980950B2 (en) 2015-03-17
PL376965A1 (pl) 2006-01-09
AP2005003320A0 (en) 2005-06-30
US20110054021A1 (en) 2011-03-03
HK1082914A1 (en) 2006-06-23
JP2006507348A (ja) 2006-03-02
AU2003291157B2 (en) 2011-01-20
US9227914B2 (en) 2016-01-05
UA81642C2 (ru) 2008-01-25
US20130158114A1 (en) 2013-06-20
BR0316544A (pt) 2005-10-04
WO2004047751A3 (en) 2004-08-19
NO20053071L (no) 2005-06-22
EA200500878A1 (ru) 2005-10-27
ES2388277T3 (es) 2012-10-11
WO2004047751A2 (en) 2004-06-10
SI1569892T1 (sl) 2012-09-28
IS2897B (is) 2014-09-15
CN1325466C (zh) 2007-07-11
US20090163589A1 (en) 2009-06-25
EP1569892A2 (en) 2005-09-07
KR101142697B1 (ko) 2012-05-10
NO332304B1 (no) 2012-08-20
MY143244A (en) 2011-04-15
AU2003291157A1 (en) 2004-06-18
EP1569892A4 (en) 2010-09-15
ZA200504104B (en) 2006-03-29
CA2507226C (en) 2011-11-15
AR042132A1 (es) 2005-06-08
AP2113A (en) 2010-03-04
DK1569892T3 (da) 2012-08-27
MA27528A1 (fr) 2005-09-01
IL168704A (en) 2010-12-30
TW200510276A (en) 2005-03-16
UY28089A1 (es) 2004-06-30
PT1569892E (pt) 2012-09-06
US8586631B2 (en) 2013-11-19
IS7880A (is) 2005-06-02
NZ540275A (en) 2007-11-30
CY1113083T1 (el) 2016-04-13
US8399517B2 (en) 2013-03-19
KR20050086786A (ko) 2005-08-30
MXPA05005574A (es) 2005-07-27
EP1569892B1 (en) 2012-06-13
US7829594B2 (en) 2010-11-09

Similar Documents

Publication Publication Date Title
CO5570664A2 (es) Derivados de acidos 2-hidroxi-3(2-indan-2-il-1,1-dimetil-etilamino)-propoxi-fenil-propionico y composiciones farmaceuticas que los contienen como agentes calciliticos
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
CO5170521A1 (es) Compuestos farmaceuticos de pirimidinona
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
PA8494101A1 (es) Derivados heterociclicos utiles como agentes anticancerosos
AR035716A1 (es) Compuestos agonistas del receptor beta3-adrenergico, uso de los mismos en la fabricacion de medicamentos y composiciones farmaceuticas conteniendo los mismos
AR032072A1 (es) Derivados de quinuclidina novedosos y composiciones medicinales que los contienen
CU23132A3 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
AR045859A1 (es) Derivados de dibenzoazepina y de benzodiazepinas sustitudos, procesos de preparacion y usos
CO5540286A2 (es) Derivados naftil indol sustituidos
BR0112475A (pt) N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina
AR028985A1 (es) Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene
ES2167710T3 (es) Tiofenopirimidinas.
CU23413B7 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos
AR018705A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos.
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
TW200612195A (en) Oxime derivatives and the use therof as latent acids
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
DK1074542T3 (da) Sulfonamidholdige indolforbindelser
NZ307505A (en) Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
AR049464A1 (es) Antagonistas de receptores de acetilcolina muscarinicos. composiciones farmaceuticas
AR055171A1 (es) Derivados de carboxamida como antagonistas del receptor muscarinico
MXPA05007494A (es) Nuevos compuestos.
CO4980859A1 (es) Arilpiperazinas que tienen actividad sobre el receptor 1a de la serotonina

Legal Events

Date Code Title Description
FG Application granted